Penumbra, Inc. (NYSE:PEN) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in Penumbra, Inc. (NYSE:PEN - Free Report) by 16.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,025 shares of the company's stock after buying an additional 2,559 shares during the period. Barclays PLC's holdings in Penumbra were worth $3,502,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. True Wealth Design LLC purchased a new position in Penumbra during the third quarter valued at $26,000. GAMMA Investing LLC raised its position in shares of Penumbra by 111.1% in the third quarter. GAMMA Investing LLC now owns 171 shares of the company's stock valued at $33,000 after buying an additional 90 shares during the last quarter. Park Place Capital Corp boosted its holdings in shares of Penumbra by 1,473.9% during the 3rd quarter. Park Place Capital Corp now owns 362 shares of the company's stock worth $70,000 after purchasing an additional 339 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Penumbra by 1,845.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company's stock worth $70,000 after acquiring an additional 369 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its holdings in shares of Penumbra by 11.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company's stock worth $81,000 after acquiring an additional 43 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a report on Thursday, October 31st. Wells Fargo & Company upgraded shares of Penumbra from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $190.00 to $275.00 in a report on Wednesday, December 11th. Canaccord Genuity Group lifted their target price on Penumbra from $260.00 to $323.00 and gave the company a "buy" rating in a research report on Monday, December 9th. BTIG Research lifted their target price on shares of Penumbra from $232.00 to $270.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Finally, Robert W. Baird boosted their price target on shares of Penumbra from $244.00 to $248.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Penumbra currently has a consensus rating of "Moderate Buy" and an average target price of $258.00.

Penumbra Stock Performance

PEN traded down $1.99 during trading on Monday, hitting $240.55. 213,405 shares of the stock were exchanged, compared to its average volume of 377,591. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $277.34. The stock has a fifty day moving average price of $232.15 and a two-hundred day moving average price of $203.76. The firm has a market capitalization of $9.23 billion, a P/E ratio of 279.71, a PEG ratio of 2.47 and a beta of 0.51.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.16. The business had revenue of $301.04 million for the quarter, compared to analysts' expectations of $297.36 million. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The company's quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. As a group, sell-side analysts predict that Penumbra, Inc. will post 2.81 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In related news, CEO Adam Elsesser sold 15,000 shares of the firm's stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $204.56, for a total value of $3,068,400.00. Following the completion of the sale, the chief executive officer now owns 867,582 shares in the company, valued at $177,472,573.92. This trade represents a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $190.76, for a total transaction of $114,456.00. Following the completion of the transaction, the executive vice president now owns 60,488 shares of the company's stock, valued at $11,538,690.88. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,418 shares of company stock valued at $7,659,323 in the last ninety days. Insiders own 5.00% of the company's stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.